Doris A. Taylor

Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction.

LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.

Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.

Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart Failure: The FOCUS-CCTRN Trial.

Effects of myocardial infarction on the distribution and transport of nutrients and oxygen in porcine myocardium.

Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.

Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN).

Building solutions for cardiovascular disease in women.

Optimizing recellularization of whole decellularized heart extracellular matrix.

Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices.

Experimental orthotopic transplantation of a tissue-engineered oesophagus in rats.

Ethics of bioengineering organs and tissues.

Bone marrow mononuclear cell therapy for acute myocardial infarction: a perspective from the cardiovascular cell therapy research network.

Automated decellularization of intact, human-sized lungs for tissue engineering.

Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes.

Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial.

Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells.

Recruiting for Acute Myocardial Infarction Cell Therapy Trials: Challenges and Best Practices for the CCTRN.

Acellular human heart matrix: A critical step toward whole heart grafts.

Changing of the guard?

Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial.

Orthotopic transplantation of a tissue engineered diaphragm in rats.

Report of the National Heart, Lung, and Blood Institute Working Group on Sex Differences Research in Cardiovascular Disease: Scientific Questions and Challenges.

Myocardial commitment from human pluripotent stem cells: Rapid production of human heart grafts.

Data from acellular human heart matrix.

Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.

Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials.

Inverted orientation improves decellularization of whole porcine hearts.

Maximizing Cardiac Repair: Should We Focus on the Cells or on the Matrix?

Optimized method for isolating highly purified and functional porcine aortic endothelial and smooth muscle cells.

Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells).

Response to letter to Editor "Comment on 'Inverted orientation improves decellularization of whole porcine hearts' by Lee et al."

Bioengineering Hearts: Simple yet Complex.

The ubiquitin-proteasome system: A potential therapeutic target for heart failure.

Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1β- and IL-6-Related Impairment of Bone Marrow Function.

Circulating Biomarkers to Identify Responders in Cardiac Cell therapy.

Premature atherosclerosis in premenopausal women: Does cytokine balance play a role?

TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis.

Texas Heart Institute International Symposium on Cardiovascular Regenerative Medicine.

Recellularization of rat liver: An in vitro model for assessing human drug metabolism and liver biology.

Mobilizing EPCs: It is not just an acute issue.

Author Correction: Circulating Biomarkers to Identify Responders in Cardiac Cell therapy.

Decellularized matrices in regenerative medicine.

Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit Cardiac Stem Cells As Regenerative Therapy for Heart Failure).

Progress in experimental and clinical subpulmonary assistance for Fontan circulation.

Building a Total Bioartificial Heart: Harnessing Nature to Overcome the Current Hurdles.

Leadless multisite pacing: A feasibility study using wireless power transfer based on Langendorff rodent heart models.

Whole Cardiac Tissue Bioscaffolds.

What will it take before a bioengineered heart will be implanted in patients?

A Path Forward for Regenerative Medicine.

Racial Disparities in CD34+ Cells and Their Influence on Cardiovascular Repair.